ToxStrategies Acquires Suttons Creek

ToxStrategies Acquires Clintrex Research Corporation

June 25, 2024

Healthcare Services

ToxStrategies, a Renovus Capital Partners–backed scientific consulting firm based in Katy, Texas, has acquired Clintrex Research Corporation, a Sarasota-based clinical and regulatory development services provider focused on neurodegenerative and CNS therapies. The deal (terms undisclosed) expands ToxStrategies' clinical, regulatory, biostatistics and drug‑development capabilities and is intended to broaden its end‑market reach in the life sciences sector.

Renovus Capital Partners Majority Investment in ToxStrategies

January 24, 2023

Healthcare Services

Renovus Capital Partners made a majority investment in ToxStrategies, a multidisciplinary scientific consulting firm specializing in toxicology, epidemiology, exposure sciences and regulatory compliance. Five Points Capital provided debt and equity co-investment to support the transaction; terms were not disclosed and the deal was described as a recapitalization to support growth and expand services, staff and geographic reach.

Renovus-Backed BlueRidge Life Sciences Formed by Uniting Suttons Creek, Modality Solutions, CLINTREX and ToxStrategies

August 25, 2025

Healthcare Services

Four life-sciences consulting firms — Suttons Creek, Modality Solutions, CLINTREX, and ToxStrategies — have been unified under the new brand BlueRidge Life Sciences to create an integrated life-sciences services platform. The move, backed by private equity sponsor Renovus Capital Partners, consolidates toxicology, regulatory science, engineering, clinical research and related capabilities to offer end-to-end scientific and regulatory support to pharmaceutical, biotech, medical device and consumer-product clients.

ToxStrategies (Renovus-backed) Acquires Modality Solutions

August 8, 2023

Healthcare Services

ToxStrategies, a Renovus Capital Partners-backed life sciences consulting platform, has acquired Modality Solutions, a Houston-based firm specializing in biopharmaceutical cold-chain optimization and shipping validation testing. The add-on expands ToxStrategies' cold-chain, package engineering, and regulatory testing capabilities and will operate as a division of ToxStrategies with Modality's founders continuing to lead the business.

Charles River Associates Acquires bioStrategies Group

November 29, 2022

Consulting

Charles River Associates (CRA) acquired substantially all assets of bioStrategies Group, a Chicago-based life sciences commercial strategy consulting firm, and retained 17 employees. The deal expands CRA's Life Sciences Practice capabilities and geographic presence by adding experienced consultants including Mike Kaestle and Chris Schneider.

Bain & Company Acquires Sutton Place Strategies

December 21, 2020

Data & Analytics

Bain & Company has acquired Sutton Place Strategies (SPS), a deal origination tool and transaction database used by private equity firms, corporate M&A teams, and deal advisors. The acquisition adds SPS's proprietary transaction data and analytics to Bain's suite of data offerings to enhance deal sourcing, pipeline analytics, and M&A advisory capabilities.